• Live Feeds
    • Press Releases
    • Insider Trading
    • FDA Approvals
    • Analyst Ratings
    • Insider Trading
    • SEC filings
    • Market insights
  • Analyst Ratings
  • Alerts
  • Subscriptions
  • AI Executive AssistantNEW
  • Settings
  • RSS Feeds
Quantisnow Logo
  • Live Feeds
    • Press Releases
    • Insider Trading
    • FDA Approvals
    • Analyst Ratings
    • Insider Trading
    • SEC filings
    • Market insights
  • Analyst Ratings
  • Alerts
  • Subscriptions
  • AI Executive AssistantNEW
  • Settings
  • RSS Feeds
PublishGo to AppAI Helper
    Quantisnow Logo

    © 2025 quantisnow.com
    Democratizing insights since 2022

    Services
    Live news feedsRSS FeedsAlertsPublish with Us
    Company
    AboutQuantisnow PlusContactJobsAI employees for your businessNEW
    Legal
    Terms of usePrivacy policyCookie policy

    Neurocrine Biosciences Appoints Dr. Sanjay Keswani as Chief Medical Officer

    4/4/25 8:00:00 AM ET
    $NBIX
    Biotechnology: Biological Products (No Diagnostic Substances)
    Health Care
    Get the next $NBIX alert in real time by email
    • Accomplished physician-scientist brings more than 20 years of industry leadership experience and broad R&D expertise in multiple therapeutic areas 

    SAN DIEGO, April 4, 2025 /PRNewswire/ -- Neurocrine Biosciences, Inc. (NASDAQ:NBIX) today announced the appointment of Sanjay Keswani, M.D., to the company's executive management team as Chief Medical Officer (CMO) effective June 2, 2025. Dr. Keswani, an accomplished physician-scientist who has more than 20 years of pharmaceutical industry experience with broad R&D expertise in multiple therapeutic areas, will lead the clinical development and medical affairs activities at Neurocrine. Dr. Keswani succeeds Eiry W. Roberts, M.D., who has served as CMO for the past seven years and who will remain with Neurocrine in a strategic advisory role.

    "Sanjay brings a wealth of strategic and development expertise to our team, enhancing our capabilities as we enter an exciting and pivotal time for the company," said Kyle W. Gano, Ph.D., Chief Executive Officer, Neurocrine Biosciences. "His contributions will extend our reach beyond small molecule medicines, enabling us to explore new modalities across our therapeutic areas of focus."

    "I am thrilled to be joining Neurocrine at this stage of the company's evolution. I am drawn by Neurocrine's enduring R&D commitment to developing much-needed treatments for patients using a rigorous scientific approach involving diverse modalities, including small molecule, peptide, antibody and gene therapy," Dr. Keswani said.

    Dr. Keswani has more than two decades of executive leadership experience across both large pharmaceutical companies and small biotechnology firms – and was instrumental in the development of several first-in-class and best-in-class approved medicines. Before joining Neurocrine, he was the President and Chief Executive Officer of ImmunoBrain, a clinical-stage biotechnology firm focused on developing therapeutics that leverage endogenous neuroimmune communication to promote brain repair in patients with neurodegenerative diseases. Dr. Keswani will continue to serve on ImmunoBrain's board of directors. Before that, he was Senior Vice President and R&D Head for Neuroscience, Ophthalmology and Rare Diseases at Hoffman La Roche. Earlier, he was Vice President of Exploratory and Clinical Translational Research at Bristol-Myers Squibb, where he was responsible for multiple therapeutic areas, including immunology, neuroscience, rare diseases, fibrosis and virology.

    Dr. Keswani is an elected Fellow of the Royal College of Physicians, United Kingdom, and a former Neurology Faculty member at The Johns Hopkins Hospital, where he cared for patients with diverse neurological conditions and ran an RO1-funded Neuroimmunology research laboratory, focused on discovering treatments for neurodegeneration. He graduated with honors at St. Bartholomew's Hospital and holds a First-Class honors BSc degree from St. Mary's Hospital, London in Pathology & Basic Medical Sciences (Immunology). He completed his residency in Neurology and fellowships in Neuroimmunology and Neurophysiology at The Johns Hopkins Hospital.

    During her tenure, Dr. Roberts led indication expansion efforts for INGREZZA® (valbenazine) capsules and the crinecerfont development program that led to U.S. Food and Drug Administration approval of CRENESSITY™ (crinecerfont). She also was responsible for the recent successful Phase 2 proof of concept studies for osavampator and NBI-1117568, both of which are moving into registrational programs this year.

    "Since joining Neurocrine in 2018, Eiry has made enormous positive contributions that helped us become the company we are today," Dr. Gano said. "She built an outstanding clinical development team and broadened our internal capabilities, which are now a competitive advantage. We are grateful to continue benefiting from her experience and expertise as she transitions into a strategic advisory role for the company."

    About Neurocrine Biosciences

    Neurocrine Biosciences is a leading neuroscience-focused, biopharmaceutical company with a simple purpose: to relieve suffering for people with great needs. We are dedicated to discovering and developing life-changing treatments for patients with under-addressed neurological, neuroendocrine and neuropsychiatric disorders. The company's diverse portfolio includes FDA-approved treatments for tardive dyskinesia, chorea associated with Huntington's disease, classic congenital adrenal hyperplasia, endometriosis* and uterine fibroids*, as well as a robust pipeline including multiple compounds in mid- to late-phase clinical development across our core therapeutic areas. For three decades, we have applied our unique insight into neuroscience and the interconnections between brain and body systems to treat complex conditions. We relentlessly pursue medicines to ease the burden of debilitating diseases and disorders, because you deserve brave science. For more information, visit neurocrine.com, and follow the company on LinkedIn, X, and Facebook. (*in collaboration with AbbVie)

    NEUROCRINE, the NEUROCRINE BIOSCIENCES Logo, YOU DESERVE BRAVE SCIENCE, and INGREZZA are registered trademarks of Neurocrine Biosciences, Inc. CRENESSITY is a trademark of Neurocrine Biosciences, Inc.

    Forward Looking Statements

    In addition to historical facts, this press release contains forward-looking statements that involve a number of risks and uncertainties. These statements include, but are not limited to, statements regarding our ability to execute on the Company's clinical development plans, including investigating new modalities in neurology and immunology, and the contributions Dr. Keswani may make in his role with the Company. Factors that could cause actual results to differ materially from those stated or implied in the forward-looking statements include, but are not limited to, the following: the risk that the Company may not complete the leadership transition within currently anticipated timelines or at all; challenges that the Company may encounter in implementing the leadership transition; risks and uncertainties associated with Neurocrine Biosciences' business and finances in general, risks and uncertainties associated with the commercialization of INGREZZA and CRENESSITY; risks related to the development of our product candidates; risks associated with our dependence on third parties for development, manufacturing, and commercialization activities for our products and product candidates, and our ability to manage these third parties; risks that the FDA or other regulatory authorities may make adverse decisions regarding our products or product candidates; risks that development activities may not be initiated or completed on time or at all, or may be delayed for regulatory, manufacturing, or other reasons, may not be successful or replicate previous clinical trial results, may fail to demonstrate that our product candidates are safe and effective, or may not be predictive of real-world results or of results in subsequent clinical trials; risks that the potential benefits of the agreements with our collaboration partners may never be realized; risks that our products, and/or our product candidates may be precluded from commercialization by the proprietary or regulatory rights of third parties, or have unintended side effects, adverse reactions or incidents of misuse; risks associated with government and third-party regulatory and/or policy efforts which may, among other things, impose sales and pharmaceutical pricing controls on our products or limit coverage and/or reimbursement for our products; risks associated with competition from other therapies or products, including potential generic entrants for our products; and other risks described in our periodic reports filed with the Securities and Exchange Commission, including our Annual Report on Form 10-K for the year ended December 31, 2024. Neurocrine Biosciences disclaims any obligation to update the statements contained in this presentation after the date hereof other than as required by law.

     © 2025 Neurocrine Biosciences, Inc. All Rights Reserved. 04/2025 

    (PRNewsfoto/Neurocrine Biosciences, Inc.)

    Cision View original content to download multimedia:https://www.prnewswire.com/news-releases/neurocrine-biosciences-appoints-dr-sanjay-keswani-as-chief-medical-officer-302420443.html

    SOURCE Neurocrine Biosciences, Inc.

    Get the next $NBIX alert in real time by email

    Crush Q3 2025 with the Best AI Executive Assistant

    Stay ahead of the competition with Tailforce.ai - your AI-powered business intelligence partner.

    AI-Powered Inbox
    Context-aware email replies
    Strategic Decision Support
    Get Started with Tailforce.ai

    Recent Analyst Ratings for
    $NBIX

    DatePrice TargetRatingAnalyst
    7/21/2025$163.00Buy
    Truist
    7/10/2025$182.00Buy
    Goldman
    4/15/2025$138.00Hold → Buy
    Needham
    4/14/2025$137.00Sector Perform → Outperform
    RBC Capital Mkts
    2/11/2025$138.00Hold
    Deutsche Bank
    10/10/2024$155.00Outperform
    Raymond James
    8/29/2024$131.00 → $159.00Neutral → Overweight
    Piper Sandler
    4/24/2024$140.00 → $170.00Equal Weight → Overweight
    Wells Fargo
    More analyst ratings

    $NBIX
    FDA approvals

    Live FDA approvals issued by the Food and Drug Administration and FDA breaking news

    See more
    • December 13, 2024 - FDA Approves New Treatment for Congenital Adrenal Hyperplasia

      For Immediate Release: December 13, 2024 Today, the U.S. Food and Drug Administration approved Crenessity (crinecerfont) to be used together with glucocorticoids (steroids) to control androgen (a testosterone-like hormone) levels in adults and pediatric patients 4 years of age and older with classic congenital adrenal hyperplasia (CAH).“Today’s approval provides an important advance for patients with classic con

      12/13/24 5:54:17 PM ET
      $NBIX
      Biotechnology: Biological Products (No Diagnostic Substances)
      Health Care

    $NBIX
    SEC Filings

    See more
    • Neurocrine Biosciences Inc. filed SEC Form 8-K: Leadership Update, Financial Statements and Exhibits

      8-K - NEUROCRINE BIOSCIENCES INC (0000914475) (Filer)

      5/30/25 4:05:10 PM ET
      $NBIX
      Biotechnology: Biological Products (No Diagnostic Substances)
      Health Care
    • Neurocrine Biosciences Inc. filed SEC Form 8-K: Leadership Update, Submission of Matters to a Vote of Security Holders

      8-K - NEUROCRINE BIOSCIENCES INC (0000914475) (Filer)

      5/22/25 4:03:59 PM ET
      $NBIX
      Biotechnology: Biological Products (No Diagnostic Substances)
      Health Care
    • SEC Form S-8 POS filed by Neurocrine Biosciences Inc.

      S-8 POS - NEUROCRINE BIOSCIENCES INC (0000914475) (Filer)

      5/21/25 5:28:04 PM ET
      $NBIX
      Biotechnology: Biological Products (No Diagnostic Substances)
      Health Care

    $NBIX
    Insider Trading

    Insider transactions reveal critical sentiment about the company from key stakeholders. See them live in this feed.

    See more
    • Chief Regulatory Officer Delaet Ingrid exercised 457 shares at a strike of $79.02 and sold $61,695 worth of shares (457 units at $135.00) (SEC Form 4)

      4 - NEUROCRINE BIOSCIENCES INC (0000914475) (Issuer)

      7/11/25 5:15:12 PM ET
      $NBIX
      Biotechnology: Biological Products (No Diagnostic Substances)
      Health Care
    • Chief Scientific Officer Onyia Jude exercised 59,819 shares at a strike of $84.74 and sold $7,803,688 worth of shares (59,819 units at $130.46) (SEC Form 4)

      4 - NEUROCRINE BIOSCIENCES INC (0000914475) (Issuer)

      7/11/25 5:01:03 PM ET
      $NBIX
      Biotechnology: Biological Products (No Diagnostic Substances)
      Health Care
    • Chief Scientific Officer Onyia Jude sold $2,649,738 worth of shares (20,362 units at $130.13) and exercised 20,362 shares at a strike of $84.74 (SEC Form 4)

      4 - NEUROCRINE BIOSCIENCES INC (0000914475) (Issuer)

      7/7/25 4:10:27 PM ET
      $NBIX
      Biotechnology: Biological Products (No Diagnostic Substances)
      Health Care

    $NBIX
    Analyst Ratings

    Analyst ratings in real time. Analyst ratings have a very high impact on the underlying stock. See them live in this feed.

    See more
    • Truist initiated coverage on Neurocrine Biosciences with a new price target

      Truist initiated coverage of Neurocrine Biosciences with a rating of Buy and set a new price target of $163.00

      7/21/25 8:37:42 AM ET
      $NBIX
      Biotechnology: Biological Products (No Diagnostic Substances)
      Health Care
    • Goldman initiated coverage on Neurocrine Biosciences with a new price target

      Goldman initiated coverage of Neurocrine Biosciences with a rating of Buy and set a new price target of $182.00

      7/10/25 8:58:47 AM ET
      $NBIX
      Biotechnology: Biological Products (No Diagnostic Substances)
      Health Care
    • Neurocrine Biosciences upgraded by Needham with a new price target

      Needham upgraded Neurocrine Biosciences from Hold to Buy and set a new price target of $138.00

      4/15/25 7:52:35 AM ET
      $NBIX
      Biotechnology: Biological Products (No Diagnostic Substances)
      Health Care

    $NBIX
    Press Releases

    Fastest customizable press release news feed in the world

    See more
    • Neurocrine Biosciences Leverages PicnicHealth to Reveal Critical Care Gaps for Patients with Rare Genetic Condition

      Technology-enabled research approach and AI-powered analysis identify unmet needs in patients with congenital adrenal hyperplasia SAN FRANCISCO, July 15, 2025 /PRNewswire/ -- PicnicHealth, a health technology company dedicated to advancing the next generation of non-interventional research, today announced its research collaboration with Neurocrine Biosciences, Inc. (NASDAQ:NBIX), the CAHtalog® Registry, identified an unmet need in patients with classic congenital adrenal hyperplasia (CAH). Using PicnicHealth's AI-powered technology to curate medical records and enable remote participation, the study revealed that CAH patients require lifelong, continuous adjustments to glucocorticoid dosing

      7/15/25 9:00:00 AM ET
      $NBIX
      Biotechnology: Biological Products (No Diagnostic Substances)
      Health Care
    • Neurocrine Biosciences Presents New Analysis of CAHtalog® Registry Showing Most Patients with Classic Congenital Adrenal Hyperplasia Experienced High Glucocorticoid Exposure, Suboptimal Disease Control or Both at ENDO 2025

      Approximately 95% of adult and pediatric patients were exposed to supraphysiologic doses of glucocorticoids and/or experienced elevated androstenedione levels at least once during their treatment journeyReal-world findings underscore long-term challenges of managing classic congenital adrenal hyperplasia and highlight clinical need for therapies to reduce androgen excess without high glucocorticoid dosesSAN DIEGO, July 15, 2025 /PRNewswire/ -- Neurocrine Biosciences, Inc. (NASDAQ:NBIX) today announced results from a new analysis using real-world data from CAHtalog®, a comprehensive registry of patients with classic congenital adrenal hyperplasia in the United States. The analysis demonstrate

      7/15/25 8:30:00 AM ET
      $NBIX
      Biotechnology: Biological Products (No Diagnostic Substances)
      Health Care
    • Neurocrine Biosciences Presented One-Year Data from Phase 3 CAHtalyst™ Studies Showing Improvements in Weight-Related Effects of Glucocorticoid Treatment at the 2025 Endocrine Society's Annual Meeting

      Adult and pediatric patients with classic congenital adrenal hyperplasia treated with CRENESSITY® (crinecerfont) achieved clinically meaningful weight reductionsSubstantial improvements in insulin resistance were also observed in both adult and pediatric patients treated with CRENESSITY compared with placebo through one year of treatmentSAN DIEGO, July 14, 2025 /PRNewswire/ -- Neurocrine Biosciences, Inc. (NASDAQ:NBIX) today announced the presentation of new data from the Phase 3 CAHtalyst™ Adult and Pediatric studies showing favorable trends in improvement of weight-related outcomes in patients with classic congenital adrenal hyperplasia who were treated with CRENESSITY® (crinecerfont) for

      7/14/25 4:35:00 PM ET
      $NBIX
      Biotechnology: Biological Products (No Diagnostic Substances)
      Health Care

    $NBIX
    Leadership Updates

    Live Leadership Updates

    See more
    • Neurocrine Biosciences Appoints Lewis Choi as Chief Information Officer

      SAN DIEGO, June 9, 2025 /PRNewswire/ -- Neurocrine Biosciences, Inc. (NASDAQ:NBIX) today announced the appointment of Lewis Choi as Chief Information Officer, effective June 9, 2025. Choi, an accomplished leader with 25 years of experience in information technology and artificial intelligence, will be responsible for driving the vision and long-term strategic direction of the company's technology initiatives. "Lewis is a proven global healthcare leader with a track record of utilizing technology to drive both cultural and technological change," said Matt Abernethy, Chief Finan

      6/9/25 4:05:00 PM ET
      $NBIX
      Biotechnology: Biological Products (No Diagnostic Substances)
      Health Care
    • Fate Therapeutics Appoints Matthew Abernethy, M.B.A., to its Board of Directors

      SAN DIEGO, May 30, 2025 (GLOBE NEWSWIRE) -- Fate Therapeutics, Inc. (NASDAQ:FATE), a clinical-stage biopharmaceutical company dedicated to bringing a pipeline of induced pluripotent stem cell (iPSC)-derived off-the-shelf cellular immunotherapies to patients, today announced the appointment of Matthew Abernethy, M.B.A., to its Board of Directors effective as of May 29, 2025. Mr. Abernethy brings to the Company over 15 years' experience in corporate finance and investor relations in the biotech and medical device industry. In addition, the Company announced that Timothy P. Coughlin stepped down from the Board of Directors, effective concurrently with Mr. Abernethy's appointment. "Mr. Aberne

      5/30/25 4:30:14 PM ET
      $FATE
      $NBIX
      Biotechnology: Biological Products (No Diagnostic Substances)
      Health Care
    • Neurocrine Biosciences Appoints Dr. Sanjay Keswani as Chief Medical Officer

      Accomplished physician-scientist brings more than 20 years of industry leadership experience and broad R&D expertise in multiple therapeutic areas SAN DIEGO, April 4, 2025 /PRNewswire/ -- Neurocrine Biosciences, Inc. (NASDAQ:NBIX) today announced the appointment of Sanjay Keswani, M.D., to the company's executive management team as Chief Medical Officer (CMO) effective June 2, 2025. Dr. Keswani, an accomplished physician-scientist who has more than 20 years of pharmaceutical industry experience with broad R&D expertise in multiple therapeutic areas, will lead the clinical development and medical affairs activities at Neurocrine. Dr. Keswani succeeds Eiry W. Roberts, M.D., who has served as C

      4/4/25 8:00:00 AM ET
      $NBIX
      Biotechnology: Biological Products (No Diagnostic Substances)
      Health Care

    $NBIX
    Financials

    Live finance-specific insights

    See more
    • Neurocrine Biosciences Announces Conference Call and Webcast of Second Quarter 2025 Financial Results

      Conference Call and Webcast Scheduled for Wednesday, July 30 SAN DIEGO, July 9, 2025 /PRNewswire/ -- Neurocrine Biosciences, Inc. (NASDAQ:NBIX) announced today that it has scheduled its second quarter 2025 financial results conference call and webcast for 1:30 p.m. Pacific Time (4:30 p.m. Eastern Time) on July 30, 2025. The schedule for the press release and conference call / webcast is as follows: Q2 2025 Press Release: July 30, 2025 at 1:00 p.m. PT / 4:00 p.m. ETQ2 2025 Conference Call: July 30, 2025 at 1:30 p.m. PT / 4:30 p.m. ETDomestic Dial-In Number: 800-225-9448Internat

      7/9/25 4:01:00 PM ET
      $NBIX
      Biotechnology: Biological Products (No Diagnostic Substances)
      Health Care
    • Neurocrine Biosciences Reports First Quarter 2025 Financial Results and Reaffirms 2025 Financial Guidance

      INGREZZA® (valbenazine) First-Quarter 2025 Net Product Sales of $545 Million and Reaffirms 2025 Net Product Sales Guidance of $2.5 - $2.6 Billion CRENESSITYTM (crinecerfont) First-Quarter 2025 Net Product Sales of $14.5 Million with 413 Total Patient Enrollment Start Forms Initiated Phase 3 Registrational Programs for Osavampator in Major Depressive Disorder and NBI-'568 in Schizophrenia to Position for Next Phase of Growth SAN DIEGO, May 5, 2025 /PRNewswire/ -- Neurocrine Biosciences, Inc. (NASDAQ:NBIX) today announced its financial results for the first quarter ended March 31, 2025, and reaffirms its 2025 financial guidance.

      5/5/25 4:01:00 PM ET
      $NBIX
      Biotechnology: Biological Products (No Diagnostic Substances)
      Health Care
    • Neurocrine Biosciences Announces Conference Call and Webcast of First Quarter 2025 Financial Results

      Conference Call and Webcast Scheduled for Monday, May 5 SAN DIEGO, April 14, 2025 /PRNewswire/ -- Neurocrine Biosciences, Inc. (NASDAQ:NBIX) announced today that it has scheduled its first quarter 2025 financial results conference call and webcast for 1:30 p.m. Pacific Time (4:30 p.m. Eastern Time) on May 5, 2025. The schedule for the press release and conference call / webcast is as follows: Q1 2025 Press Release: May 5, 2025 at 1:00 p.m. PT / 4:00 p.m. ETQ1 2025 Conference Call: May 5, 2025 at 1:30 p.m. PT / 4:30 p.m. ETDomestic Dial-In Number: 800-245-3047International Dial

      4/14/25 4:01:00 PM ET
      $NBIX
      Biotechnology: Biological Products (No Diagnostic Substances)
      Health Care

    $NBIX
    Large Ownership Changes

    This live feed shows all institutional transactions in real time.

    See more
    • SEC Form SC 13G filed by Neurocrine Biosciences Inc.

      SC 13G - NEUROCRINE BIOSCIENCES INC (0000914475) (Subject)

      10/17/24 9:54:01 AM ET
      $NBIX
      Biotechnology: Biological Products (No Diagnostic Substances)
      Health Care
    • SEC Form SC 13G/A filed by Neurocrine Biosciences Inc. (Amendment)

      SC 13G/A - NEUROCRINE BIOSCIENCES INC (0000914475) (Subject)

      2/9/23 11:27:44 AM ET
      $NBIX
      Biotechnology: Biological Products (No Diagnostic Substances)
      Health Care
    • SEC Form SC 13G/A filed by Neurocrine Biosciences Inc. (Amendment)

      SC 13G/A - NEUROCRINE BIOSCIENCES INC (0000914475) (Subject)

      2/14/22 2:34:19 PM ET
      $NBIX
      Biotechnology: Biological Products (No Diagnostic Substances)
      Health Care